Memorial Sloan Kettering Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Memorial Sloan Kettering Cancer Center sits in the top decile of US sponsors by registered trial count (#6 of 15,751 sponsors by registered trial count).
Memorial Sloan Kettering Cancer Center: 1,884 sponsored US clinical trials, 327 recruiting.
Memorial Sloan Kettering Cancer Center sponsors 1,884 registered US clinical trials on ClinicalTrials.gov, 327 of them currently recruiting, and 1,104 completed. 75 of these trials are in Phase 3-4 (later-stage) and 1,101 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 98 trials.
Top-decile sponsor footprint
Memorial Sloan Kettering Cancer Center ranks in the top decile of sponsors by registered trial count (#6 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
1,884 total, page 36 of 38
10-Propargyl-10-Deazaaminopterin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
NCT00004238
Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma
NCT00004066
Vaccine Therapy in Treating Patients With Myelodysplastic Syndrome
NCT00003959
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
NCT00005633
Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer
NCT00005632
Temozolomide in Treating Patients With Recurrent Malignant Glioma
NCT00004113
Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors
NCT00004922
Vaccine Therapy in Treating Patients With Breast Cancer
NCT00004156
Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer
NCT00004061
Combination Chemotherapy in Treating Patients With Advanced Cancer
NCT00003956
Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas
NCT00003923
Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia
NCT00004052
PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma
NCT00004152
Rebeccamycin Analog in Treating Children With Relapsed or Refractory Neuroblastoma
NCT00003737
Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT00004012
Combination Chemotherapy and Surgery in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma
NCT00003776
Paclitaxel Plus L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphomas
NCT00004057
Monoclonal Antibody F19 in Treating Patients With Advanced or Metastatic Cancer
NCT00004042
Trastuzumab in Treating Patients With Prostate Cancer
NCT00003740
Ro 31-7453 in Treating Patients With Locally Advanced or Metastatic Solid Tumor
NCT00003755
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors
NCT00003742
Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell Cancers
NCT00003658
McGhan Medical Silicone-Filled Breast Implant Adjunct Study
NCT00581984
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Central Nervous System Lymphoma
NCT00003632
Combination Chemotherapy and Biological Therapy in Treating Patients With High-Risk Ewing's Sarcoma
NCT00003667
Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients Who Have Chronic Lymphocytic Leukemia
NCT00003659
Thalidomide and Cyclophosphamide in Treating Children With Recurrent or Refractory Childhood Cancers
NCT00003754
Floxuridine, Dexamethasone, and Irinotecan After Surgery in Treating Patients With Liver Metastases From Colorectal Cancer
NCT00003753
Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma
NCT00003631
Irinotecan in Treating Patients With Advanced Solid Tumors
NCT00004051
Vaccine Therapy Plus QS21 in Treating Patients With Small Cell Lung Cancer That Has Responded to Initial Therapy
NCT00004249
Arsenic Trioxide in Treating Patients With Advanced Solid Tumors
NCT00003630
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
NCT00003443
Utility of PET In the Pre-Operative Assessment of Patients With Hepatic Colorectal Metastases
NCT00588549
Monoclonal Antibody Therapy Plus Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
NCT00003543
Irinotecan in Treating Patients With Metastatic Colorectal Cancer
NCT00003544
Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer
NCT00003819
Combination Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma
NCT00003541
6-Hydroxymethylacylfulvene in Treating Patients With Metastatic Kidney Cancer
NCT00003390
Gemcitabine in Treating Women With Metastatic Breast Cancer Previously Treated With Doxorubicin and Paclitaxel
NCT00003540
Hormone Therapy in Treating Women With Breast Cancer
NCT00003428
Interferon Alfa in Treating Patients With Advanced Kidney Cancer
NCT00003542
PET Scans in Diagnosing Primary or Recurrent Cervical Cancer in Patients Who Are Undergoing Surgery
NCT00003429
Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma
NCT00003362
Diet and PSA Levels in Patients With Prostate Cancer
NCT00003367
L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors
NCT00003430
Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer
NCT00003395
Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Colorectal Cancer
NCT00003360
Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer
NCT00003394
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
NCT00003426
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 461 |
| Phase 2 | 640 |
| Phase 3 | 67 |
| Phase 4 | 8 |
Therapeutic Areas
What is open in the Memorial Sloan Kettering Cancer Center pipeline
327 recruiting of 1,884 indexed (17% open); 1,104 completed (59%).
Phase mix: 75 late (III/IV) vs 1,101 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (98 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.